ACROBiosystems/Human Fc gamma RIIIA / CD16a (V176) Protein, His Tag (SPR & BLI verified)/1mg (500ug X 2)/CD8

价格
¥36000.00
货号:CD8
浏览量:127
品牌:ACROBiosystems
服务
全国联保
正品保证
正规发票
签订合同
商品描述
  • Synonym
    FCGR3A,CD16A,FCG3,FCGR3,IGFR3
  • Source
    Human CD16a (V176), His Tag (SPR& BLI verified) (CD8-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
    Predicted N-terminus: Gly 17
    Request for sequence
  • Molecular Characterization
    Online(Gly 17 - Gln 208) P08637-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 23.7 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by reduced SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;

    2. -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE
Human CD16a (V176), His Tag (SPR& BLI verified) (Cat. No. CD8-H52H4) SDS-PAGE gel

Human CD16a (V176), His Tag (SPR& BLI verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

ImmobilizedHuman CD16a (V176), His Tag (SPR& BLI verified) (Cat. No.CD8-H52H4) on CM5 Chip via anti-His antibody, can bindHerceptinwith anaffinity constant of 163 nM as determined in SPR assay (BiacoreT200) (QC tested).

Protocol
Human_FcRn_Heterodimer_Protein_SPR
Report
Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD16a (V176), His Tag (SPR& BLI verified) (Cat. No. CD8-H52H4) on HIS1K Biosensor, can bind Herceptin with an affinity constant of 0.447 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
Human_FcRn_Heterodimer_Protein_Bli

Loaded Herceptin on Protein A Biosensor, can bind Human CD16a (V176), His Tag (SPR & BLI verified) (Cat. No. CD8-H52H4) with an affinity constant of 0.37 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
Human_FcRn_Heterodimer_Protein_Bli

Loaded Herceptin on FAB2G Biosensor, can bind Human CD16a (V176), His Tag (SPR & BLI verified) (Cat. No. CD8-H52H4) with an affinity constant of 0.31 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
  • Citations
    • Charge variant analysis of proposed biosimilar to Trastuzumab

      Authors: Dakshinamurthy P, et al.

      Journal: Biologicals 2017

      Application: SPR

      Request for Full-text

  • Background
    CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
  • References
    • (1)Webster NL., et al., 2006, J Leukoc Biol. 79: 294-302.

    • (2)Nagarajan S., et al., 1995, J Biol Chem. 270: 25762-70.

    • (3)Ravetch JV., 1989, J.Exp.Med.170:481.

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

ACROBiosystems治疗性抗体的功效不仅取决于Fab片段及其与靶抗原的结合活性,还取决于Fc片段及其与关键Fc受体的相互作用。Fc片段对FcRn的结合亲和力(FCGRT&B2M)将预测抗体的半衰期,而Fc片段与FcγRIIIa(CD16a)之间的结合亲和力将影响抗体引发ADCC的能力(抗体依赖性细胞介导的细胞毒性)。因此,必须在抗体工程化过程中针对一组受体测试候选人。ACROBiosystems提供了完整的重组Fc受体蛋白集合,包括它们的常见变体,以帮助您加快mAb的开发。